antitubercular agent-30

Antitubercular agent-30 has antitubercular activity.

Antitubercular agent-41 is a antibacterial agent.

Antimalarial agent 30 has anti-Plasmodium berghei liver stage parasite activity and antimalarial activity for the study of malarial infections.

Antitubercular agent-10 exhibits potent antitubercular activity with a MIC value of 30 nM.

Antitubercular agent-39 (Compound P1) is a potent agent effective against both drug-resistant and drug-susceptible clinical isolates of tuberculosis, inhibiting the Mtb strain H37Rv with a minimum inhibitory concentration (MIC) of less than 1 μM [1].

Antibacterial agent 30 exhibits remarkable in vitro activity against Xoo, as evidenced by its EC50 value of 1.9 μg/mL.

Antitubercular agent-36 (compound 53) is an effective inhibitor of Mycobacterium tuberculosis H37Rv, with a minimum inhibitory concentration (MIC90) of 1.25 μg mL, and is utilized in tuberculosis research [1].

Antitubercular agent-29 (compound 6xa) is a potent Mycobacterium tuberculosis (Mtb) inhibitor, effective against drug-resistant (DR) and drug-susceptible (DS) strains with a minimum inhibitory concentration (MIC) of 0.03 μg mL for DS-Mtb and 0.03-0.06 μg mL for DR-Mtb strains, and demonstrates favorable selectivity (SI>40) against Vero cells.

Antitubercular agent-31 is an antitubercular agent that inhibits M. tuberculosisH37Rv (MIC: 0.03 μM) and also inhibits DprE1 (IC50: 1.1 μM).

Antitubercular agent-19 is an antitubercular agent. antitubercular agent-19 showed good antitubercular effects against MTB H37Rv and MDR-MTB (MIC <0.016 μg/ml). antitubercular agent-19 showed low cytotoxicity and relatively high acute lethality in BALB/c mice. Antitubercular agent-19 exhibited low cytotoxicity and relatively high acute lethal toxicity in BALB/c mice.

Antitubercular Agent-37 exhibits antimycobacterial properties and functions as an antibacterial agent with an MIC (minimum inhibitory concentration) value of 0.16 μg/mL, making it suitable for tuberculosis research [1].

Antitubercular agent-23 is an effective anti-Candida and anti-tuberculosis agent against Candida albicans MTCC 3017 (MIC: 1.1 μg/ml) and M. tuberculosis (H37Rv) (MIC: 1 μg/ml).

Antitubercular agent-9 exhibits potent activity against tuberculosis, demonstrating a minimum inhibitory concentration (MIC) range of 1.03-2.32 μM.

Antitubercular agent-32 is a Benzothiazinone derivative that inhibits Mycobacterium tuberculosis and exhibits good metabolic stability and water solubility. Antitubercular agent-32 can act on decaprenylphosphoryl-β-D-ribose 2'-oxidase (DprE1, IC50: 3.9 μM) and exhibits antitubercular effects.

Antitubercular agent 34 (compound 42g) effectively inhibits Mtb H37Rv growth with a MIC 90 value of 1.25 µg mL and demonstrates resistance to metabolic degradation by human liver microsomes, indicating its potential for tuberculosis research [1].

Antitubercular agent-17 (Compound 8a) is an efficacious antitubercular agent, demonstrating Minimum Inhibitory Concentration (MIC) values of 2 μg ml against M. tuberculosis H37Rv, Spec. 192, and Spec. 210, and 128 μg ml against Spec. 800. It exhibits highly selective antimycobacterial effects [1].

Antitubercular agent-12 (Compound 2c) is a highly effective antitubercular agent with a MIC (Minimum Inhibitory Concentration) value of 1.439 μg mL and significantly reduced cytotoxicity, evidenced by a CC50 (50% Cytotoxic Concentration) value of 57.34 μg mL [1].

Antitubercular agent-13 (Compound 3d) is an antitubercular compound with MIC values of 0.007 μg mL against MTB H37Rv and 1.851 μg mL against MDR-MTB 16833, respectively, and exhibits metabolic instability [1].

Antitubercular Agent-38, a derivative of Benzothiazinones (BTZs), demonstrates potent antituberculosis activity while maintaining low cardiac toxicity and minimal cell cytotoxicity [1]. This orally active compound is a promising therapeutic in the treatment of tuberculosis.

Antiproliferative agent-30 (Compound 8g) exhibits broad-spectrum antiproliferative activity, with IC50 values of 0.054 nM, 0.008 nM, and 0.144 nM against HCT-116, K562, and MV-4-11 cancer cell lines, respectively. It inhibits tubulin assembly, FLT3, and Abl1 kinases and shows vascular-disrupting capabilities. Additionally, it displays an anticancer effect against acute myeloid leukemia (AML) with FLT3-ITD-TKD mutations [1].

Antitubercular agent-21 (Compound 15) is an antitubercular agent with low cytotoxicity, exhibiting an MIC of 0.4 μg mL against M. tuberculosis H37Rv. However, it shows lower activity against other microorganisms, including gram-positive bacteria, gram-negative bacteria, and fungi [1].

Antitubercular agent-16 (Compound 5q) is a potent antitubercular agent exhibiting high efficacy against various strains of M. tuberculosis, including H37Rv, CF16, CF61, CF76, CF152, and CF161, with MIC 90 values ranging from 0.40 to 23.51 μg mL. Notably, Antitubercular agent-16 demonstrates minimal cytotoxicity towards macrophages and pulmonary fibroblasts, further highlighting its potential as a therapeutic agent [1].

Antitubercular agent-20 is an orally active antitubercular agent. agent-20 showed low cytotoxicity and good tolerability in BALB/c mice.

Antitubercular agent-25 (Compound 28) is an anti-tubercular agent with an extracellular IC50 of 0.42 μM and an intracellular IC50 of 0.20 μM against M. tuberculosis H37Rv, and it demonstrates good metabolic stability.

Antitubercular agent-27 (compound 1) exhibits potent antitubercular properties with an IC50 of 3.2 μM, an MIC of 7.8 μM, and an IC90 of 7.0 μM, effectively targeting resistant Mycobacterium tuberculosis H37Rv isolates and displaying significant intracellular antimycobacterial activity with low cytotoxicity [1].

Antitubercular agent-14 (Compound 1) exhibits antitubercular activity with an MIC value of 0.3 μg mL against M. tuberculosis [1].

Antitubercular agent-18 (Compound 9a) is an antitubercular agent that exhibits highly selective antimycobacterial effects, with minimum inhibitory concentration (MIC) values of 2 μg ml against M. tuberculosis H37Rv, Spec. 192, and Spec. 210, and 128 μg ml against Spec. 800, demonstrating its efficacy in inhibiting the growth of these mycobacterial strains [1].

Antifungal agent 30 is a potent antifungal agent that exhibits good antifungal activity against Candida albicans (CPCC400616) (MIC: 0.03 μg/mL) and Aspergillus fumigatus (MIC: 0.5 μg/mL). Antifungal agent 30 exerts antifungal activity through hydrogen and ligand interactions with CYP51.

Antiviral Agent 30 (Example 118) is an active compound against HCV and RSV with an inhibitory concentration (IC 50) of greater than 25μM [1].

Antitubercular Agent-35 (compound 42l) is an antitubercular agent effective against Mtb H37Rv and M. Marinum, exhibiting MIC 90 values of 1.25 and 2 μg/mL, respectively. It demonstrates resistance to metabolic degradation by human liver microsomes, rendering it a potential candidate for tuberculosis research [1].

Antitubercular agent-26 (Compound 32) is an orally active agent targeting M. tuberculosis H37Rv cells with an IC50 of 0.50 μM extracellularly and 0.51 μM intracellularly. It exhibits good metabolic stability, a low risk of cardiotoxicity, and no genotoxicity.

Compound 5 (Anti-inflammatory agent 30) exhibits anti-inflammatory properties and demonstrates hepatoprotective activity [1].

Anticancer agent 30 (compound 6f-Z) is a potent 3-arylidene-2-oxindole derivative that acts as a selective CDK2 inhibitor, showing significant anticancer activity and potential as a cancer treatment [1].

Antitubercular agent-22 (Compound 2) is an effective antimicrobial agent against Candida albicans MTCC 3017 (MIC: 2.34 μg ml) and M. tuberculosis (H37Rv) (MIC: 2 μg ml).

Antitubercular agent-24 (Compound 1) exhibits anti-tubercular properties against M. tuberculosis H37Rv, demonstrating an extracellular IC50 of 0.83 μM and an intracellular IC50 of 0.17 μM [1].

Antitubercular agent-15 (Compound 5n) is an antitubercular agent with low cytotoxicity against pulmonary fibroblasts and macrophages. The MIC90 values against M. tuberculosis H37Rv, CF16, CF61, CF76, CF152, and CF161 are 0.73, 7.69, 9.38, 18.80, 7.53, and 7.31 μg mL, respectively [1].

Antitubercular agent-11 (Compound 1e) contains a bulkier electron-donating group (Bu-t) and exhibits the best MIC value of 0.060 μg mL [1].

Antitubercular agent-28 (compound 2) exhibits antimycobacterial activity against resistant isolates of Mycobacterium tuberculosis H37Rv with an MIC of 4.5 μM, an IC50 of 1.5 μM, and an IC90 of 2.5 μM. It demonstrates effective intracellular antimycobacterial activity with low cytotoxicity [1].